+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Ovulation Test Market Size was valued at USD 2.4 Billion in 2022. The Ovulation Test market industry is projected to grow from USD 2.8 Billion in 2023 to USD 4.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.60% during the forecast period (2023 - 2032). Globally, there are more and more illnesses emerging, including Polycystic Ovary Syndrome (PCOS), other health problems, more first-time mothers, and poor fertility rates, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Type: Secondary Research, Primary Research, Research Layer Database and Analyst Review
The rise in conditions like Polycystic Ovary Syndrome (PCOS) and other health issues will fuel the market for ovulation tests. Additionally, the ovulation test market will grow in the next years due to an increase in first-time pregnancies and low fertility rates around the world. Most countries today are technologically advanced and employ digital testing techniques. Due to the rising popularity of ovulation testing in these countries and the availability of advanced technology with high accuracy, the market for ovulation tests is growing globally. As family planning becomes more well-known, it is projected that the market for ovulation testing will expand. The rise in pregnancy test kit difficulties across the board is expected to fuel the demand for ovulation tests. The 99% accurate results that the home ovulation test kit delivers at a fair price are attracting suppliers. Due to the need to avoid unwanted pregnancies and maintain improved healthcare facilities for children, this industry will expand in the coming years.
The increase in online ovulation test sales provides the industry participants with a considerable opportunity. You can buy the ovulation testing supplies at the closest pharmacy. It's not required to get a prescription to buy these devices because they are over-the-counter. This makes it easier to promote these products to internet retailers. Numerous online merchants, such as Amazon, Flipkart, and Walmart, offer these products for sale. The market participants are also putting plans into action for the online sale of the ovulation testing equipment on the company website. For their products, they have opened a personal internet store. One firm that has started selling its products online is Modern Fertility. These strategies are expected to create lucrative potential for the growth of the ovulation test market.
The Ovulation Test Market is growing as a result of increased populations of women of reproductive age, rising first-time pregnancy ages, and rising gynaecological practises. The OECD states that the average age at which women give birth is currently 30 or higher due to a greater tendency to delay first pregnancy. As a result of altering lifestyles, where women are becoming more independent and deferring childbearing until they are older, the age at which women give birth has changed. The market is also expected to grow as a result of increasing home testing equipment sales, new product development, and consumer awareness. The demand for home testing devices is increasing since they are easily accessible through e-commerce websites, pharmacies, and retail stores. For instance, many companies are forming cooperative ventures that benefit women. Prega News and Spicejet have agreed into a new arrangement to implement a number of measures to enhance the comfort of pregnant women flying. Thus, driving the Ovulation Test market revenue.
The global Ovulation Test market segmentation, based on Type, includes Urine-based Tests, Saliva-based Tests, and Other Tests. Urine-based Tests segment accounted for the largest revenue share in 2022. The urine-based tests kits category is the key engine of market growth due to increased ovulation prediction kit usage and widespread availability of over-the-counter test kits for at-home testing.
The global Ovulation Test market segmentation, based on Application, includes Hospital, Home Care Settings, Clinics, and Others. Home Care Settings segment dominated the global Ovulation Test market in 2022. This is due to the change in patients' attitudes towards self-monitoring of medical illnesses and the availability of user-friendly at-home test equipment. For instance, companies are now selling ovulation prediction kits that consumers may use at home to detect the presence of ovulation-inducing chemicals in their saliva or urine.
Download Free Sample to learn more about this report
Type: Secondary Research, Primary Research, Research Layer Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Ovulation Test Market dominated this market in 2022 (45.80%). This is because more clients are using the ovulation test kit, more clients are appropriating it, and more clients are aware of planned pregnancies. Further, the U.S. Ovulation Test market held the largest market share, and the Canada Ovulation Test market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Type: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Europe Ovulation Test market accounted for the healthy market share in 2022. This is a result of increased awareness of planned pregnancies among the general public and the availability of ovulation testing equipment through e-commerce websites. Further, the German Ovulation Test market held the largest market share, and the U.K Ovulation Test market was the fastest growing market in the European region.
The Asia Pacific Ovulation Test market is expected to register significant growth from 2023 to 2032. This is a result of the increasing use of contraceptives that assess your financial situation. Asia-Pacific must be the area with the fastest expansion in the relevant market due to the increasing subsidising and initiatives for the improvement of ripeness and ovulation screenings. This is because a growing number of women are having lifestyle problems. Moreover, China’s Ovulation Test market held the largest market share, and the Indian Ovulation Test market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Ovulation Test market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Ovulation Test industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Ovulation Test industry to benefit clients and increase the market sector. In recent years, the Ovulation Test industry has offered some of the most significant advantages to medicine. Major players in the Ovulation Test market, including Fairhaven Health LLC, Fertility Focus Limited, NecLife, Swiss Precision Diagnostics GmbH, HiLin Life Products Inc., Geratherm Medical AG, Accuquik, Church & Dwight Co. Inc., Prestige Brands Holdings Inc., Clearblue, and Piramal Healthcare, are attempting to increase market demand by investing in research and development operations.
Callitas Health Inc. is a company that is in the clinical phase. It develops technology for the monitoring and treatment of gastroenterological disorders like diabetes and obesity. The company's product range includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a moisturiser that increases conception. Increasing a woman's own natural conception lubricant, known as transudate, has been shown to aid in conception in clinical tests. Roche sells orlistat under the brand names Xenical (on prescription) and alli, which are both FDA-approved for weight loss. Extrinsa focuses on female arousal and orgasmic problems. The local, topical chemical is also non-hormonal and has no impact on the central nervous system. Callitas Health Inc., a producer of OTC goods, experimental medicines, and cannabis delivery systems, declared today that its original contract with NFI Consumer Healthcare had been modified and enlarged. The new contract calls for ToConceive and NFI's e.p.t®, the brand of OTC pregnancy test kits, to distribute a co-branded product within the food, drug, and mass retailer industries.
Crown Laboratories, a manufacturer and distributor of skincare products, seeks to develop a wide range of safe and effective scientific products for healthy skin. The company specialised in dermatology and provides a wide selection of skincare items for cosmetic, therapeutic, and pharmaceutical uses to improve the lives of its customers. The purchase of StriVectin was announced in August 2021 by Crown Laboratories, a well-known, fully integrated, global skincare company, and L Catterton, the largest global consumer-focused private equity firm and a portfolio company of Hildred Capital Management LLC. The transaction is expected to close by the middle of September 2021, subject to regulatory approvals and other customary closing requirements.
· Fairhaven Health LLC
· Fertility Focus Limited
· NecLife
· Swiss Precision Diagnostics GmbH
· HiLin Life Products Inc.
· Geratherm Medical AG
· Accuquik
· Church & Dwight Co. Inc.
· Prestige Brands Holdings Inc.
· Clearblue
· Piramal Healthcare
June 2021: BioMérieux announced the distribution of the REVEAL Rapid AST system across Europe according to certain diagnoses, boosting the demand for rapid testing kits on the region.
April 2021: Actress Jordana Brewster and Clearblue® promoted awareness of the difficulties of conception and women's fertility through the Real Talk with Conceiving Hood campaign.
· Urine-based Tests
· Saliva-based Tests
· Other Tests
· Hospital
· Home Care Settings
· Clinics
· Others
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 2.4 Billion |
|
Market Size 2023 |
USD 2.8 Billion |
|
Market Size 2032 |
USD 4.5 Billion |
|
Compound Annual Growth Rate (CAGR) |
6.60% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Application, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Fairhaven Health LLC, Fertility Focus Limited, NecLife, Swiss Precision Diagnostics GmbH, HiLin Life Products Inc., Geratherm Medical AG, Accuquik, Church & Dwight Co. Inc., Prestige Brands Holdings Inc., Clearblue, and Piramal Healthcare |
|
Key Market Opportunities |
High adoption of kits for ovulation and pregnancy testing |
|
Key Market Dynamics |
Rising various types of diseases such as Polycystic Ovary Syndrome (PCOS) and other health issues and increased number of first-time pregnancies and low fertility rates across the globe |
The global Ovulation Test market was valued at USD 2.4 billion in 2022, and it is estimated to reach USD 4.5 billion by 2032.
The global market is projected to grow at a CAGR of 6.60% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Fairhaven Health LLC, Fertility Focus Limited, NecLife, Swiss Precision Diagnostics GmbH, HiLin Life Products Inc., Geratherm Medical AG, Accuquik, Church & Dwight Co. Inc., Prestige Brands Holdings Inc., Clearblue, and Piramal Healthcare
The Urine-based Tests Type dominated the market in 2022.
The Home Care Settings Application had the largest share in the global market.
Report Code :
RL6557
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst